Key result
Higher medication adherence was associated with increased total healthcare costs (0.32 to 32.57 Euro per PDC percentage point) and pharmacy costs, but frequently lower inpatient costs.
Why the study?
Literature on medication adherence and healthcare costs suffers from methodological limitations, including lack of generalizability, varying definitions, and model specification.
Does medication adherence affect total and category-specific healthcare costs in chronically ill patients?
Cohort (n=2,644,212)
Does medication adherence affect total and category-specific healthcare costs in chronically ill patients?
In chronically ill patients, higher medication adherence is associated with increased total and pharmacy costs but decreased inpatient costs, highlighting the complex economic impact of adherence.
Higher adherence may raise total costs despite lower inpatient spending; leaves open net value of adherence programs in chronic illness.
BACKGROUND AND OBJECTIVE: Despite the importance of medication adherence for chronically ill patients and the vast literature on its relationship to costs, this field suffers from methodological limitations. These are caused, amongst others, by the lack of generalizability of data sources, varying definitions of adherence, costs, and model specification. We aim to address this with different modeling approaches and to contribute evidence on the research question. METHODS: We extracted large cohorts of nine chronic diseases (n = 6747-402,898) from German claims data of stationary health insurances between 2012 and 2015 (t0-t3). Defined as the proportion of days covered by medication, we examined the relationship of adherence using several multiple regression models at baseline year t0 with annual total healthcare costs and four sub-categories. Models with concurrent, and differently time-lagged measurements of adherence and costs were compared. Exploratively, we applied non-linear models. RESULTS: Overall, we found a positive association between the proportion of days covered by medication and total costs, a weak association with outpatient costs, positive with pharmacy costs, and frequently negative with inpatient costs. There were major differences by disease and its severity but little between years, provided adherence and costs were not measured concurrently. The fit of linear models was mainly not inferior to that of non-linear models. CONCLUSIONS: The estimated effect on total costs differed from most other studies, which highlights concerns about generalizability, although effect estimates in sub-categories were as expected. Comparison of time lags indicates the importance of avoiding concurrent measurement. A non-linear relationship should be considered. These methodological approaches are valuable in future research on adherence and its consequences.
No takes yet. Share an insight, caveat, or question.
Wendl et al. (2023) conducted a cohort in Chronic diseases (T1D, T2D, hypertension, CHF, CHD, hyperlipidemia, asthma, COPD, IBD) (n=2,644,212). Medication adherence (Proportion of Days Covered) vs. Lower medication adherence was evaluated on Annual total healthcare costs (0.32 to 32.57 Euro increase per PDC %-point). Higher medication adherence was associated with increased total healthcare costs (0.32 to 32.57 Euro per PDC percentage point) and pharmacy costs, but frequently lower inpatient costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: